ClinicalTrials.gg
RecruitingNCT07295704Updated Dec 22, 2025

Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema

An observational study in Micropulse Laser, Treatment and Initial, sponsored by The General Authority for Teaching Hospitals and Institutes. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by The General Authority for Teaching Hospitals and Institutes · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Macular Edema with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Macular Edema · Egypt.

Started
2025
with 2 others
Observational
5 of 22
2 open now
Registered
20th of 22
by date

Among the 22 studies in Macular Edema with a site in Egypt, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 20th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

5 of the 22 studies in Macular Edema with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Macular Edema with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.

Read the detailed description

Diabetic Retinopathy (DR) is a common and specific microvascular complication of diabetes that affects 17-54% of people with diabetes aged between 49 and 60 years.

Diabetic macular edema (DME) is one of the most common causes of visual loss in today's society. It affects about 10% of diabetic individuals and 29% of those who have had the condition for more than 20 years.

In micropulse mode, the laser emits short pulses, thereby reducing thermal energy in the target area.

This strategy has two properties: a shorter exposure time and a subvisible clinical endpoint, delivering energy by dividing the beam into a series of short pulses (100-300 µs). Every single pulse has an "on and off" duration (duty cycle (DC)), enabling tissues to cool down before the next pulse.

03

Conditions studied

  • Micropulse Laser
  • Treatment
  • Initial
  • Refractory
  • Center-Involved Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This prospective cohort comparative study was conducted at the Ophthalmology Department of Sohag Teaching Hospital, with approval from the institutional ethical committee.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Both sexes.
  • Patients with type 1 or 2 diabetes mellitus (DM), best-corrected visual acuity (BCVA) of 20/400 or better, and center-involved DME [defined as a central macular thickness (CMT) of >250 but \<700µm measured by spectral-domain optical coherence tomography].
  • Patients with any level of non-proliferative diabetic retinopathy or proliferative diabetic retinopathy with adequate panretinal photocoagulation (PRP) and no signs of disease activity determined by fluorescein angiography (FA).

Exclusion criteria

Exclusion Criteria:

  • Monocular eyes.
  • Chronic renal failure or renal transplant because of diabetic nephropathy.
  • (HbA1c) of more than 10%.
  • Vitreomacular traction syndrome.
  • Epiretinal membrane.
  • PRP within 4months before the treatment.
  • Intraocular surgery within 6months, including cataract or vitreoretinal operation.
  • Rubeosis iridis.
  • Severe glaucoma.
  • High-risk proliferative diabetic retinopathy.
  • Poor dilation.
  • Increased foveal avascular zone.
  • Any condition that could interfere with optical coherence tomography (OCT) measurement or visual acuity.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Naïve center-involved diabetic macular edema group

    Patients with treatment-naïve center-involved diabetic macular edema.

    Other: Micropulse Laser

  • Refractory center-involved diabetic macular edema group

    Patients with refractory center-involved diabetic macular edema.

    Other: Micropulse Laser

Interventions

  • OtherMicropulse Laser

    All laser procedures will be performed in a darkened room. The laser will be delivered together in an 8×8 pattern mode with high density (0µm of spacing) over the entire area of macular edema, including the foveal center and unthickened (200µm) retina with no attempt to target or avoid microaneurysms.

06

What researchers measure

Primary outcomes

  1. Change of best-corrected visual acuity

    Change of best-corrected visual acuity will be recorded.

    Time frame: 6 months post-procedure

Secondary outcomes

  1. Change of central macular thickness

    Change of central macular thickness will be recorded.

    Time frame: 6 months post-procedure

  2. Change of area thickness

    Change of area thickness will be recorded.

    Time frame: 6 months post-procedure

  3. Change of macular volume

    Change of macular volume will be recorded.

    Time frame: 6 months post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2026, 5 months after the start.

Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2025
First posted
Dec 22, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Mar 30, 2026
CompletionEst.
Mar 30, 2026
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07295704
Lead sponsor
The General Authority for Teaching Hospitals and Institutes
Responsible party
Hossam Abdelfattah Husein Hassan (Fellow of Ophthalmology, Sohag Teaching Hospital, Egypt., The General Authority for Teaching Hospitals and Institutes) — Principal investigator
First posted
Dec 22, 2025
Start date
Oct 15, 2025
Primary completion
Mar 30, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Dec 22, 2025

Study contacts

Hossam A Hassan, MD
Contact
Dr.hossameabdalfataah@gothi.gov.eg
00201026808348

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion